An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
about
How to select the optimal treatment for first line metastatic colorectal cancerCIViC databaseRole of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population.Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancerEffects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic featuresA polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysisMolecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.Suppression of colorectal cancer metastasis by nigericin through inhibition of epithelial-mesenchymal transition.Epigenetic mechanisms in commonly occurring cancers.MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinomaEffects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology.Epigenetic biomarkers in colorectal cancer diagnostics.Examining the impact of gene variants on histone lysine methylationEpigenetic mechanisms of tumorigenicity manifesting in stem cells.Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.Histone Chaperone ASF1A Predicts Poor Outcomes for Patients With Gastrointestinal Cancer and Drives Cancer Progression by Stimulating Transcription of β-Catenin Target Genes.Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population.The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.A genetic variant in microRNA target site of TGF-β signaling pathway increases the risk of colorectal cancer in a Chinese population.The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females.Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population.Methyltransferase expression and tumor suppressor gene methylation in sporadic and familial colorectal cancer
P2860
Q27026516-F6E4032E-33CE-4F12-BFE2-7E7241F279CDQ27612411-D154BA4B-545F-4297-B210-29E60267B7E1Q34072487-41D98B16-342C-4E6B-AC36-E5105FF80626Q34226978-9E667DAD-87E7-4735-8E3D-832F40D55519Q34990394-185FDF9C-CB47-4EAE-BE90-F73B994FBF40Q35137483-E5E2936E-02D8-4265-9047-C3B0AA02E805Q35163440-0B8C3AF0-10CF-49E4-9985-4DAD14C7FE79Q35606640-B17A9989-E673-4AD1-A10B-816C88C44D44Q35836756-6911B11C-644F-4808-980F-9EF639500491Q36016020-43D90FF6-8A39-450F-B6FD-DA4F1F86A17BQ36286662-C0C24C54-5DE8-4890-BE88-E7D99358C5EDQ36394758-8E81CD81-FB1B-48F6-A8B4-AD82DCBA47EEQ36420195-ABED6ED5-0E32-4ACF-B2C5-22B63AD4961BQ38018997-FA0EC38E-DEA3-4D97-9624-8DEFCB11D365Q38214535-B55E02E0-446E-4B23-B081-47ABB74C4E79Q38220397-025C51CE-0221-4C26-BF2C-744C357874CFQ38312076-0E3BA06C-60E7-4B59-968D-FFF419F21092Q38594002-F64AD80A-6766-4484-8304-E4C9D74340A8Q38975402-643B17D7-A037-49C8-AA40-6650ED58E5ADQ38993869-C8CF2797-B807-4BDE-A0CF-BDA51594D144Q41040835-3D301C91-1BAC-4E89-A1CB-A2167C262D10Q42688119-BEB9059D-5E8F-4C6C-B249-C61C3E439676Q45144714-733A2330-7CA7-47CE-A183-E386A49029B5Q46732136-1FE834C1-3AD7-41F6-80B0-0E383648608AQ53244367-A62D86C9-7D43-4839-B127-0D5671AB74EBQ53432255-834E596C-89F1-4FBA-9137-31632C3BD470Q54224805-E9FD1D3E-7C19-4826-B6E1-01138E968BBBQ59272744-520C1598-FC69-421D-BCED-04E3BEF4AB3E
P2860
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@ast
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@en
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@nl
type
label
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@ast
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@en
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@nl
prefLabel
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@ast
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@en
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@nl
P2093
P356
P1433
P1476
An EZH2 polymorphism is associ ...... ic colorectal cancer patients.
@en
P2093
C Cremolini
F Graziano
F Loupakis
L Salvatore
M Schirripa
P304
P356
10.1093/ANNONC/MDR387
P577
2012-05-01T00:00:00Z